2014
DOI: 10.1016/j.ejpb.2014.09.007
|View full text |Cite
|
Sign up to set email alerts
|

Design of silica carrier for controlled release of molsidomine: Effect of preparation methods of silica matrixes and their composites with molsidomine on the drug release kinetics in vitro

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
4
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 13 publications
(5 citation statements)
references
References 51 publications
1
4
0
Order By: Relevance
“…The release exponent n is in the range of 0.13-0.29 (<0.43), suggesting the diffusion-controlled release is by Fickian diffusion mechanism instead of corrosion. These results are in a good agreement with the previous reports of Hahn et al [37] and Parfenyuk et al [38] . Evidently, two factors including salt cation and pH should be considered as the release forces.…”
Section: Resultssupporting
confidence: 94%
“…The release exponent n is in the range of 0.13-0.29 (<0.43), suggesting the diffusion-controlled release is by Fickian diffusion mechanism instead of corrosion. These results are in a good agreement with the previous reports of Hahn et al [37] and Parfenyuk et al [38] . Evidently, two factors including salt cation and pH should be considered as the release forces.…”
Section: Resultssupporting
confidence: 94%
“…Modern medicine focuses on local therapy [82] and it is believed that employing silica composites in local drug distribution has some benefits including: (1) the capacity to integrate significant quantities of broadly scattered or dissolved drugs at low temperatures during solidification procedures, (2) the assurance of efficient stabilization of the drug load towards deterioration due to moderately well host-guest interactions, (3) the regulated kinetics of drug release by adjusting the porous silica structure characteristics. Medicinal drugs such as molsidomine [83], bisphosphonate [84], itraconazole [85], ibuprofen, doxorubicin (DOX) [86], and vancomycin [87] have also been integrated into silica compounds, providing many potentials for both regulated deliveries of medicines and effective local therapy [88].…”
Section: Silica Composite Drug Carriersmentioning
confidence: 99%
“…The traditional routes to PSP are alkoxysilanes (Parfenyuk and Dolinina, 2014;Mohseni, 2015;Parfenyuk and Dolinina, 2017;Kierys, 2020). However, the toxicity of alkoxysilanes is well documented (Nakashima, 1998), and besides, their high cost (Essien, 2012) renders them unattractive for large-scale synthesis of PSP.…”
Section: Introductionmentioning
confidence: 99%